Panelists:
Angela M. Cacace, PhD
Chief Scientific Officer
Arvinas
- Time:
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s remain some of the most challenging conditions to treat. Despite decades of research, small molecule inhibitors have shown limited clinical benefit for treating misfolded proteins, while amyloid-beta-focused approaches have been shown to address only one of many underlying disease drivers. Repeated late-stage failures have underscored the biological complexity of these disorders.
Targeted protein degradation is emerging as a promising modality for eliminating disease-driving proteins. By selectively reducing pathogenic protein levels, degraders may offer a way to address neurodegenerative and neuromuscular diseases by targeting proteins that lack conventional druggable sites.
In this GEN webinar, our expert speaker will discuss the increasing rationale for targeting key drivers of neurological disease with protein degraders and how this approach may enable deeper, more precise modulation of disease biology. Key takeaways from the webinar will include:
- Targeted protein degradation could help address the underlying biology of neurodegenerative and neuromuscular diseases.
- Protein degraders are designed to selectively eliminate disease-driving proteins that have historically been difficult or impossible to target, potentially expanding the range of tractable targets in neurology.
- In preclinical experiments, certain protein degraders have shown the ability to reach the target in the brain or muscle, reduce the disease-associated protein, and affect downstream biological pathways.
A live Q&A session will follow the presentation offering you a chance to pose questions to our expert speaker.
Produced with support from:
